Noteworthy Thursday Option Activity: VST, BSX, KLAC

Boston Scientific (BSX) saw 47,257 option contracts trade today, equivalent to roughly 4.7 million underlying shares or 56.2% of its one‑month ADTV of 8.4 million shares; the $80 put expiring April 17, 2026 accounted for 8,745 contracts (~874,500 shares). KLA Corp (KLAC) recorded 4,271 option contracts (~427,100 shares), about 49.5% of its one‑month ADTV of 862,240 shares, with concentrated activity in the $1360 put expiring January 16, 2026 (478 contracts, ~47,800 shares). Concentrated put flow in both names suggests significant hedging or bearish positioning that could affect near‑term option-implied volatility and stock flow dynamics.

Analysis

Market structure: The oversized BSX put flow (8,745 contracts = 874,500 shares, ~10.4% of BSX’s ADV; total option flow ~4.7M shares = 56% of ADV) concentrates downside interest around the $80 April‑17‑2026 strike, pressuring implied volatility and creating one-way dealer gamma exposure. Dealers selling these puts will delta‑hedge by shorting stock on weakness, amplifying intraday downside; counterparties could be hedgers or directional speculators anticipating >10% downside into Apr‑2026. KLAC’s concentrated January $1,360 put flow (~47.8k shares, ~5.5% ADV) signals investor concern over semiconductor capex; that weakens sentiment across capex suppliers and raises implied vol in the group.

Risk assessment: Immediate risks (days–weeks) are dealer delta‑hedge feedback and IV spikes; short‑term (weeks–months) risks include company‑specific catalysts (BSX device recalls, KLAC order misses) and macro shocks (Fed pivot, capex cut). Tail scenarios: a BSX clinical/regulatory surprise or a sudden semicapex collapse could drive >30% moves and force structured product deleveraging. Hidden dependency: large put blocks may be portfolio hedges for structured notes—unwinding would flood shares if volatility squeezes sellers.

Trade implications: Prioritize option‑based directional trades rather than large naked equity positions. For BSX, favor defined‑risk bearish spreads into Apr‑2026; for KLAC, favor relative shorts vs ASML/NTNX in the semicapex theme and consider long‑dated put calendars to capture realized vol. Size positions so single‑name risk <2–3% portfolio; trim sector exposure to semiconductor equipment by 20–30% if KLAC guidance or orders miss in the next 60 days.

Key Decisions for Investors

• Establish a defined‑risk bearish position on BSX: buy Apr‑17‑2026 $80/$70 put spread sized to 2% portfolio risk (max loss = premium). Exit if BSX closes above $95 for 10 consecutive trading days or if implied vol for the Apr stack collapses >30% from today’s level.
• Reduce KLAC outright long exposure by 25–40% within 2 weeks; initiate a 6–9 month pair trade: short KLAC and long ASML (equal dollar) to express a capex share‑shift view. Close if KLAC outperforms ASML by >15% or if KLAC issues positive order guidance within 60 days.
• If selling premium, target short 30–60 day OTM put credit spreads in healthcare equipment names (e.g., BSX, MDT) only when IV percentile >70 and limit max loss to 1–2% portfolio per name; collect outsized credit from skew while capping tail risk.
• Trigger alerts and increase short exposure to 3–5% on BSX or KLAC if company reports revenue/orders down >5% QoQ or issues guidance cut within next 60 days; if no negative catalyst within 90 days, reduce bearish sizing by half to capture potential IV decay.